ImmuCell to Announce Unaudited Financial Results for First Quarter of 2020
May 07 2020 - 12:00PM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically-proven and
practical products that improve the health and productivity of
dairy and beef calves, will report unaudited financial results for
the quarter ended March 31, 2020 after the market closes on
Wednesday, May 13, 2020.
The Company has scheduled a conference call the next morning,
Thursday, May 14, 2020, at 9:00 AM ET to review the results.
Interested parties can access the conference call scheduled by
the Company to review these results by dialing (844) 855-9502 (toll
free) or (412) 317-5499 (international) at 9:00 AM ET on Thursday,
May 14, 2020. A teleconference replay of the call will be available
for six days at (877) 344-7529 (toll free) or (412) 317-0088
(international), utilizing confirmation #10143957.
The Company expects to file its Quarterly Report on Form 10-Q on
Wednesday, May 13, 2020. Investors are encouraged to review the
Company’s updated Corporate Presentation slide deck that provides
an overview of the Company’s business which will be posted under
the “Investors” tab of the Company’s website at www.immucell.com
after the market closes on Wednesday, May 13, 2020, or by request
to the Company.
About ImmuCell: ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create
scientifically-proven and practical products that improve the
health and productivity of dairy and beef calves. ImmuCell
manufactures and markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain™, a novel treatment for subclinical
mastitis without a milk discard requirement that provides an
alternative to traditional antibiotics. Press releases and other
information about the Company are available at:
http://www.immucell.com.
Contact:
Michael F. Brigham, President and CEOImmuCell Corporation(207)
878-2770
Joe Diaz, Robert Blum and Joe DorameLytham Partners, LLC(602)
889-9700iccc@lythampartners.com
Cautionary Note Regarding Forward-Looking Statements
(Safe Harbor Statement):
This Press Release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to: our
plans and strategies for our business; projections of future
financial or operational performance; the timing and outcome of
pending or anticipated applications for regulatory approvals;
factors that may affect the dairy and beef industries and future
demand for our products; the extent, nature and duration of the
COVID-19 pandemic and its consequences, and their direct and
indirect impacts on the Company’s production activities, operating
results and financial condition and on the customers and markets
the Company serves; the scope and timing of ongoing and future
product development work and commercialization of our products;
future costs of product development efforts; the estimated
prevalence rate of subclinical mastitis and dairy producers’ level
of interest in treating subclinical mastitis given current economic
and market conditions; the expected efficacy of new products;
estimates about the market size for our products; future market
share of and revenue generated by current products and products
still in development; our ability to increase production output and
reduce costs of goods sold associated with our new product,
Tri-Shield First Defense®; the
future adequacy of our own manufacturing facilities or those of
third parties with which we have contractual relationships to meet
demand for our products on a timely basis; the anticipated costs of
(or time to complete) planned expansions of our manufacturing
facilities and the adequacy of our funds available for these
projects; the continuing availability to us on reasonable terms of
third-party providers of critical products or services; the
robustness of our manufacturing processes and related technical
issues; estimates about our production capacity, efficiency and
yield; the future adequacy of our working capital and the
availability and cost of third-party financing; future regulatory
requirements relating to our products; future expense ratios and
margins; future compliance with bank debt covenants; costs
associated with sustaining compliance with current Good
Manufacturing Practice (cGMP) regulations in our current operations
and attaining such compliance for the facility to produce the Nisin
Drug Substance; implementation of international trade tariffs that
could reduce the export of dairy products, which could in turn
weaken the price received by our customers for their products; our
effectiveness in competing against competitors within both our
existing and our anticipated product markets; the
cost-effectiveness of additional sales and marketing expenditures
and resources; anticipated changes in our manufacturing
capabilities and efficiencies; the value of our net deferred tax
assets; projections about depreciation expense and its impact on
income for book and tax return purposes; anticipated market
conditions; and any other statements that are not historical facts.
Forward-looking statements can be identified by the use of words
such as “expects”, “may”, “anticipates”, “aims”, “intends”,
“would”, “could”, “should”, “will”, “plans”, “believes”,
“estimates”, “targets”, “projects”, “forecasts”, “seeks” and
similar words and expressions. In addition, there can be no
assurance that future developments affecting us will be those that
we anticipate. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties
relating to difficulties or delays in development, testing,
regulatory approval, production and marketing of our products
(including the First Defense® product line and
Re-Tain™), competition within our anticipated
product markets, customer acceptance of our new and existing
products, product performance, alignment between our manufacturing
resources and product demand, our reliance upon third parties for
financial support, products and services, changes in laws and
regulations, decision making and delays by regulatory authorities,
currency values and fluctuations and other risks detailed from time
to time in filings we make with the SEC, including our Quarterly
Reports on Form 10-Q, our Annual Reports on Form 10-K and our
Current Reports on Form 8-K. Such statements involve risks and
uncertainties and are based on our current expectations, but actual
results may differ materially due to various factors, including the
risk factors summarized above.
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024